Allogeneic CAR‑T Achieves 42% MRD Boost, Safe Profile
Allogene $ALLO cema-cel interim ALPHA3 results just reported: B-cell lymphoma MRD negativity: cema-cel 58% vs observation 16% A 42% absolute difference in MRD clearance is better than expected. Clean safety profile, too. Allogeneic CAR-T may have found its role. Nice to see.
NVS Sells Darovasertib for $6M in Cash, Stock
Let's remember again that $NVS dumped off darovasertib for $2.5m in cash + $3.5m in $IDYA series B preferred stock.
Spyre's SPY001 Achieves 40% Remission in UC Trial
Spyre $SYRE just reported SPY001 (long-acting alpha4beta7 antibody) ulcerative colitis induction data. Here's the efficacy chart, notable for a 40% clinical remission rate at week 12, albeit with small number of patients. https://t.co/aEoLWPRjEL
LUT014 Shows Promise for RASi‑Induced Skin Rash
*Disclaimer : the company developing LUT014 is a Pontifax portfolio company.* Mechanistically LUT014 should be effective in RASi induced-rash as it was designed to activate RAS signaling in the skin so using it topically could de-couple RAS inhibition in the tumor...
High‑dose GLP‑1s Raise Optic Nerve Risk; Titrate Carefully
Patients are not asking if GLP-1s are right for them. They are asking how much you charge for tirzepatide. Shiv K. Goel breaks down what physicians need to know about oral Wegovy. Pharmacovigilance data: Wegovy carries nearly five times higher...
ALLO's Alpha-3 DLBCL Data Set to Spark Pre‑Market Move
Key $ALLO catalyst coming pre market today, with first data from cema-cel's Alpha-3 study in DLBCL consolidation. What to look for: https://t.co/a19BVEppqP
Darovasertib Shows Promise in Optimum-02 Uveal Melanoma Trial
$IDYA darovasertib data from registrational Optimum-02 trial in uveal melanoma are out. What to look for: https://t.co/1LQa0X6xJa
AI Powers Cancer Cures While Robots Learn Chores
AI is designing molecules that boost chemotherapy effectiveness by 70%, and humanoid robots are learning tasks by watching gig workers record themselves doing chores... we're literally teaching machines to cure cancer AND do our laundry.
Targeted mRNA Nanoparticles Halt Lung Tumors and Cachexia
Follistatin mRNA delivered via targeted lipid nanoparticles enables a dual therapeutic effect by simultaneously suppressing lung tumor growth and preventing cancer-associated muscle wasting (cachexia). https://t.co/56fCFZU0vk
IPSC Therapies Succeed; In‑vivo Reprogramming Remains Hype
your regular reminder that Yamanaka factor-driven production of iPSCs is already producing real medicine (eg dopaminergic neural progenitor for Parkinson's, cardiomyocyte sheets for heart failure & more) iPSC tech is not done in vivo... ppl isolate the well behaved cells away...
Daily Evoked Gamma Therapy Shows Safety and Cognitive Benefit
Safety, tolerability, and efficacy estimate of evoked gamma oscillation in mild to moderate Alzheimer’s disease 👉 “Our results demonstrate that 1-h daily treatment with [CogTx-001] was safe and well-tolerated and demonstrated potential clinical benefits in mild to moderate AD.” 🔘 Participants underwent...
24/7 Green Lab Services Available for $49‑$150
Great list of services from @americanwetware to ultimately have available 24/7. We have most of the green ones already in place w/ protocols in Ginkgo Cloud Lab for $49-$150, still need to add solubility measurement but can do that...
AbbVie’s Mirvetuximab Shows
AbbVie combo mirvetuximab posts 62.7% ORR; median DOR 11.2m. Efficacy boosts pipeline vs rich valuation and R&D hit. Trading insight: buy on pullback ahead of catalysts. 📈 — Viktor Kopylov, PhD, CFA More insights: t.me/si14Kopylov
Drugs May Slow, but Not Fully Reverse Aging
Just like we can't turn a human into a naked mole rat with drugs (requires too many specific molecular changes), I don't think we will fully reverse ageing pharmacologically. We may be able to slow human ageing with drugs, but reversing...
A Decade of DNA Innovation Powers AI‑Biology Convergence
Ten years ago, Emily Leproust had an idea to rewrite how DNA gets made. Most people thought it wouldn't work. Today, Twist Bioscience is the infrastructure layer for biotech and pharma worldwide. At SynBioBeta 2026, she's on the main stage with John...
Rare Diseases Need Molecular Surgery, Not Drug Barriers
The turning point for rare diseases, which affect >300 million people around the world. A call to get rid of its many structural obstacles, to consider it as molecular surgery unlike drug treatments gift link: https://t.co/DQ0OZ9tXXc https://t.co/RELCwTr88i
One Blood Test Detects Multiple Cancers and Diseases
Detecting multiple cancers and other diseases from a single blood sample https://t.co/6gjjYY50dm via @medical_xpress #cancer #research
High‑dose Dexamethasone Improves Outcomes in Newly Diagnosed Myeloma
Lenalidomide + high-dose dexamethasone (RD) vs lenalidomide + low-dose dexamethasone (Rd) as initial therapy for newly diagnosed multiple myeloma: an open-label RCT [10/22/2009] @VincentRK et al. @TheLancetOncol https://t.co/hXxlFINejC #NCT00098475 #EAonc E4A03 #mmsm #caxtx #ctsm https://t.co/GnehXu71Td
Seeking Experiences with GTWY Peptide From Β‑Lactolin
New smart drug peptide alert… (Possibly): who has experience with GTWY peptide isolated from β-lactolin? Research here: https://t.co/Sg7twStXvr
Combating Rising Anti‑Vaccine Activism Through Science Advocacy
Many thanks @uiowa for hosting my lectures this week, on our vaccine development program and the dangers of accelerating antivaccine activism in America, also the history of American anti-science movements and latest book #ScienceUnderSiege with @MichaelEMann @PeterHotez https://t.co/3r0XH08iMu
Current and Future Strategies for Parkinson's Therapy
Parkinson disease therapy: current strategies and future research priorities https://t.co/5wq36T3ZQ4 Today is World Parkinson's Day 🧠https://t.co/XUVY6eSg61 Fig. 1: Pathophysiological mechanisms underlying Parkinson disease and possible disease-modifying therapies. 👇👨⚕️ https://t.co/0G7mqNA6nm
AI‑Designed Enzymes Break Evolution’s Limits for Biomanufacturing
Nature never designed enzymes for industrial manufacturing. It designed them to survive. That mismatch is one of the biggest bottlenecks in biomanufacturing — and most of the industry has been working around it with incremental fixes for decades. Matthew Thompson from Biomatter...
Poor Drug Selection Hampers Stroke Treatment Breakthroughs
1,026 experimental treatments in acute stroke (2006) "The results question whether the most efficacious drugs are being selected for stroke clinical trials. This may partially explain the slow progress in developing treatments..." https://t.co/WllAIz3Xul
Spatial Biology, Single‑cell Profiling, and AI Map T‑cell Immunity
Towards Spatial Medicine for individualized cancer immunotherapy @SciImmunology "The convergence of spatial biology platforms, single-cell immune profiling, and machine learning is positioning the community to decode how T cell immunity is spatially organized in human tissues and to exploit that organization...
Cell‑free DNA Manufacturing Eliminates Cloning Bottlenecks
Your DNA synthesis workflow is probably slowing you down more than you think. Cloning introduces delays, contamination risk, and hard limits on what you can build. Most of the field is still living with these constraints — even as mRNA therapeutics,...
Stroke Research Stuck: Preclinical Successes Fail Clinically
Translational Block in Stroke: A Constructive and “Out-of-the-Box” Reappraisal 👉"The literature is saturated by >1000 effective preclinical studies in acute stroke research... yet almost none are successfully transferred to the acute clinical routine. This is the well-known translational failure or block...
China's Biotech Surge Threatens Western Drug Dominance
Big Pharma Is Turning to China for the Newest Drug Ideas—China’s biotechs are faster and have lower costs, and its drug research threatens to soon overtake the West’s @Loftus https://t.co/YszgDfNlwc https://t.co/YszgDfNlwc
One‑sentence AI Pipeline Transforms Drug Discovery Workflow
What if your next drug discovery pipeline started with one sentence, not 6 months of scripting? In this latest deep dive with @scispace, I saw a shift that feels bigger than incremental AI gains. Upload single-cell data and get clustered cell types,...
Acting CDC Chief Stalled Release of Vaccine Benefit Study
Acting CDC director delayed release of study showing benefit of Covid vaccines - NBC News https://t.co/JsxUVy7Cpj
MIT Discovers Hundreds of Bacterial CRISPR-Like Tools
MIT Mined Bacteria for the Next CRISPR—and Found Hundreds of Potential New Tools https://t.co/n4cJpB8dVk https://t.co/Vq57AKw6XD
Self‑immunized Man’s Blood Yields Universal Antivenom
A truck mechanic from Wisconsin spent 18 years injecting himself with venom from the world's deadliest snakes. 700 doses. 200+ bites. He taught himself immunology from a textbook. His name is Tim Friede. His blood may end up saving hundreds of...
Reprogrammed Tregs Turn Pancreatic Tumors Immunotherapy‑Friendly
Reprogramming regulatory T cells within pancreatic tumors may transform them from immune suppressors into supporters of anti-tumor activity, offering a potential strategy to enhance immunotherapy effectiveness in this challenging cancer. immunotherapy
REPL RP1 Melanoma Trial Flawed; New CRL
I've never covered the REPL RP1 data in melanoma, mainly due to dislike of the trial design w/ its lack of a monotherapy arm. Sometimes you can see where things are likely headed and kicking a dog when it's down...
FDA Approves First Gene Therapy for LAD‑I Children
FDA approves first gene therapy, Kresladi, offering a breakthrough treatment for children with the rare immune disorder LAD-I https://t.co/ezWPPEgtd0
Investors Demand Immediate Release of Market-Sensitive Data
This is getting quite tiresome: first $ORIC, now $ALLO & $IDYA. Why are you sitting on market-sensitive data rather than releasing it now? https://t.co/N8q95re7ho
Reasoning Models Accelerate Science via Autonomous Lab Loops
Awesome to see. Reasoning models are going to be a massive accelerant to science. Important to connect them to autonomous labs so we can close the loop of design, experiments, data analysis and back around again.
Ezetimibe Shows Unexpected Potential to Prevent Alzheimer’s
Ezetimibe might help prevent Alzheimer's disease... but not in the way that you think. These data really caught me off guard. But the data are the data. (long-form video linked below)
OCE's Objections Caused Rejection, Not Vinay Prasad
$REPL my read of the RP1 CRL suggests OCE (CDER) took the lead in the review. Their objections led to the first rejection, as I previously reported, and nothing Replimune submitted for the second review was enough to support...
Replimune's FDA‑targeted Skin Cancer Drug Faces Another Rejection
Replimune $REPL skin cancer drug that became FDA flashpoint is rejected again https://t.co/7aOfKy8vC7 via @Jasonmmast
Psychedelic Therapies May Outpace GLP‑1s Commercially
I believe the commercial potential of #psychedelic therapies is likely to exceed that of GLP-1s. $ATAI $CMPS $DFTX
Optical Genome Mapping Enhances AML Classification and Treatment
Optical genome mapping [OGM] improves the accuracy of classification, risk stratification, & personalized treatment strategies for Pts w/ acute myeloid leukemia [Jul 17, 2024] @sanamloghavi et al. @AjHematology https://t.co/R5ZLgolhuj #AMLsm #leusm #PrecisionMedicine #oncopath https://t.co/kX7KUJLK0L
International Mega-Analysis Shows Psychedelics Alter Brain Circuit Function
An international mega-analysis of psychedelic drug effects on brain circuit function lots of great researchers involved in this paper. (whole article) https://t.co/vKhH0duJqv
Personalized CRISPR Fixes Baby KJ’s Genetic Defect
In just 6 months a team at @ChildrensPhila & @PennMedicine designed a personalized CRISPR based Rx to correct the single misspelled letter in Baby KJ’s DNA that results in CPS1 deficiency. Recent advances in mRNA science & CRISPR gene...
Biotech IPO Surge Expected; List on NYSE
Getting to know the @NYSE and Johanna and Eric has been a highlight of mine since their earliest support of BiotechTV. I have no doubt we will see a strong IPO pipeline for biotech this year, and I hope you...
NMN Daily Restores NAD, Supports Healthy Aging
David Sinclair takes 1 gram of NMN every single day. Here's why. As you age, your body loses up to 50% of a molecule called NAD. NAD is a molecule that acts like fuel powering your sirtuin genes - the genes responsible...
Young Mitochondria Transplants Could Reverse Aging and Disease
What if aging, ALS, Parkinson's, stroke, and diabetes all share a single upstream cause — and the fix is a transplant the size of a bacterium? Dr. Catherine Baucom and Van Hipp of MitoSense explain how injecting healthy young mitochondria...
New GLP‑3 Drug Reta May Target Fat, Spark Hunger
Like it or not, GLP-1-based weight loss drugs are here to stay. 1/2) What's more, people are experimenting with newer evolutions, like "reta" (retatrutide/GLP-3). As an MD PhD & metabolism scientist, I decided to start my own experiment to help answer...
Decoding ORR: What RECIST v1.1 Means for Investors
Investors will often see ORR quoted or displayed for oncology clinical trial results for solid tumors Here's what the CRs/PRs/SDs mean at a high level These are assessed on scans I'm using RECIST v1.1 definitions #learnbiotechinvesting #biotech #investing #BiotechPrometheus https://t.co/eZb86TcoLL
Advanced Biotech Delivers Precise Disease Detection
Accurate Disease Detection with Advanced Biotech Diagnostics by @antgrasso #MedTech #Healthcare #HealthTech #Tech #TechForGood https://t.co/71nTNGOdDQ
Safety and Efficacy Assessments Created to Prevent Thalidomide Disaster
The current system of assessing safety and efficacy was literally invented to avoid the best thalidomide 😃